Lyophilized Drugs, Reconstitution Devices and Injection Markets: Products, Markets, Therapeutics, Strategies & Forecasts

Description

"Lyophilized Drugs, Reconstitution Devices, and Injection Markets: Therapeutics, Strategies and Forecasts" is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for lyophilized injectable drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Evolution in Therapeutic Care

The number of drugs supplied in lyophilized form has been growing at an increased rate over the past several years, mirroring the increase in the introduction of biological drugs. Liquid drugs that require refrigeration until dispensed - a requirement referred to as the 'Cold Chain' - can be formulated as powders to avoid the cost and logistics of cold storage. A number of factors are at play that are likely to influence the future demand picture for lyophilized drugs. Perhaps the most important is the underlying dynamics of the pharmaceutical and biotechnology marketplace as they apply to drug formulation and end user requirements.

What You Will Learn:

Provides detailed analysis of lyophilized drugs, as-supplied packaging and therapeutic indication
Analyzes therapeutic demand drivers and evaluates lyophilized drugs in eleven therapeutic areas
Analyzes reconstitution technologies and market development issues
Provides market data and forecasts to 2026
Profiles market participants, their product development activities, business strategies, and corporate alliances and affiliations
Assesses the importance of technology and regulatory factors on commercialization and market access

Executive Summary

Integrated Devices for POC Reconstitution
Dual Chamber Cartridges
Dual Chamber Injectors
Dual Chamber Syringes
Wearable Device Automated Reconstitution Systems
Device Assessments
Product-Specific Devices
MiniQuick (Vetter)
Specialty Devices
Caverject Impulse (Hospira/Pfizer)
OEM Devices
Lyo-Ject (Vetter)
DCP (SHL)
Dual Chamber Safety Syringe (Credence Medsystems)
Liquid Dry (Becton Dickinson)
LyoTwist Trio/Vario (Ypsomed)
LyoTwist Trio S/Vario S (Ypsomed)
V-LK (Vetter)
The Market Opportunity
Lyophilized Drug Market Dynamics
The Economics of lyophilized Drugs
What's Driving the Market for Lyophilized Drugs?
The Trend toward Self-Administration
Shifting Demographics
Innovation in Disposable Device Designs
Competitive Landscape
Therapeutic Demand Drivers
Risk Factors
Lyophilized Drugs - Primary Packaging
Drug Reconstitution
Dual Chamber Cartridges
Dual Chamber Syringes
Prefilled Diluent Syringes
Multi-Step Devices
Human Engineering/Ergonomics
Key Therapeutic Sector Analysis & Market Data
Antibiotics & Infectious Diseases
Immune
Cardiology & Blood Factors
Metabolic Conditions
Glycemic Control
Development Stage Dual Chamber Injectable Drug Products
Osteoporosis
Hormones
Neurology
Oncology
Reproductive Health
Erectile Dysfunction
Market Factors
Regulatory Issues
Healthcare Economics
Therapeutic Segments - Data & Forecasts
Hormone Replacement
Genotropin (Pfizer)
Metabolic Conditions
Osteoporosis
Neurology
Abilify Maintena (Otsuka America Pharmaceutical)
Oncology
Lucrin (Abbott Australasia Pty)
Reproductive Health
Caverject Impulse (Hospira/Pfizer)
Edex/alprostadil (Actient)
Lupron Depot (AbbVie)
Other Therapeutic Segments
Prostap (Takeda)